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The recent tragic and widely publicised death 
of South African (SA) celebrity Gugu Zulu 
on Mount Kilimanjaro has drawn significant 
public interest and speculation about the 
risks of high-altitude trekking and climb-
ing.[1] It has also demonstrated numerous 
myths and misconceptions with regard to 
safe high-altitude ascents among not only 
the lay public, but also medical professionals. 
Kilimanjaro is of particular relevance, as it 
has a very high incidence of altitude-related 
illnesses.[2-5] Regardless of the details of the 
Zulu tragedy, a great number of southern 
Africans undertake treks on Kilimanjaro each 
year. We have a responsibility to improve 
understanding and access to medically sound 
advice for prospective adventurers, and to 
encourage tour operators to plan and market 
adventure activities that mitigate the risks to 
participants.
While the proportional composition of the 
atmosphere remains remarkably consistent, 
ambient pressure decreases logarithmically 
with ascent, causing a corresponding decrease 
in the partial pressure of oxygen (PO2).[6] 
The physiological effects of altitude are 
predomi nantly due to the resultant hypoxia 
and hypo baria. High altitude is defined as 
>1 500 m above sea level, where the phy-
sio logical effects of altitude may first be 
consistently observed, but pathological 
consequences are very rare.[7] At this level, 
the alveolar partial pressure of oxygen (PAO2) 
is ~10 kPa, compared with the sea level value 
of 13 kPa. It is worth noting that large areas 
of SA, including the extensive metropolitan 
areas in Gauteng, therefore qualify as high-
altitude areas. Above 3 500 m is referred to 
as very high altitude, above which immediate 
compensatory mechanisms no longer suffice, 
acclimatisation over time is required, and the 
incidence of acute high-altitude illness (HAI) 
due to rapid ascent increases dramatically. This 
can include the syndrome complex known 
as acute mountain sickness (AMS), or the 
more severe and life-threatening conditions, 
high-altitude cerebral or pulmonary oedema 
(HACE or HAPE). While uncommon, cases 
have occurred in the Drakensberg mountains 
(authors’ experience). Altitudes >5 500 m are 
referred to as extreme altitudes. Exposure to 
these levels without gradual acclimatisation 
will almost certainly result in severe illness.[8] 
At the top of Kilimanjaro (5 895 m, barometric 
pressure ~47 kPa), atmospheric air has a 
PO2 of only 9.4 kPa and the alveolar gas 
equation predicts that even with maximal 
hyperventilation and hypocarbia, the PAO2 can 
only approach 6 kPa (Fig. 1). This is less 
than half of the sea level value, despite ade-
quate acclimatisation. Values <3 kPa have been 
recorded in healthy climbers on Everest.[9]
The only reliable preventive measure to 
combat HAI is a slow rate of ascent to altitude, 
allowing adequate time for physiological 
acclimatisation. While most healthy indi-
viduals can acclimatise up to 5 500 m, HAI 
can be induced in any individual if the rate 
of ascent is sufficiently rapid. Contrary to 
common beliefs, youth, physical and aerobic 
fitness, gender and previous ascent to high 
altitudes offer no protection.[7] Medications 
such as acetazolamide (Diamox) may hasten 
acclimatisation, but still require a suitably slow 
ascent profile to have a protective effect.[3]
Numerous evidence- and consensus-based 
guidelines for safe ascent rates and acclimatisa-
tion exist,[8,10,11] but are not uniformly applied.[5] 
Typically, above 3 500 m, an increase in sleep-
ing altitude of ≤500 m/day is recommended, 
with a rest day for each 3 - 4 days’ climb. The 
old climber’s adage ‘climb high, sleep low’ 
may confer an advantage, but this has not 
been proven in the literature. While most 
of the world’s highest peaks lie deep within 
wilderness areas and require a lengthy trek 
to reach (and therefore time for acclimatisa-
tion), Kilimanjaro is a particularly important 
exception. As the world’s highest free-stand-
ing mountain, it allows rapid ascent from the 
surrounding lowlands (<700 m). Conversely, 
the absence of requirement for technical 
climbing skills to gain the 5 895 m summit, 
combined with the allure of one of the Seven 
Summits, draws >30 000 aspirant summiteers 
every year – many of whom have never before 
experienced extreme altitudes. While the 
trekking distances required make reaching 
the summit in 3 - 4 days easily achievable, 
acclimatising to nearly 6 km above sea level 
cannot occur in such a short time. Itineraries 
of 4 - 5 days have rates of AMS >75%,[4] while 
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Fig. 1. Relative heights of well-known African and international peaks in comparison to Kilimanjaro, 
with approximate PAO2 values and minimum duration of safe ascents (drawing by the authors, PAO2 
values calculated).
HACE incidence has been reported as 18%.[2] Indeed, consensus 
statements in the wilderness medical literature indicate that ascents 
of <7 days carry very high risks.[10] In contrast to this lies the com-
mercial imperative: every day on Kilimanjaro incurs additional guid-
ing, porter, camping, national park and rescue fees, all of which create 
a perverse incentive to hurry, imposed by the almighty dollar. This is 
further compounded by the pressure placed on the guides by compa-
nies and climbers alike, for whom summit success is paramount.
It is important to recognise that AMS symptoms are nonspecific 
(headache, nausea, vomiting, gastrointestinal upset, fatigue and 
poor sleep) and mimic common conditions such as influenza.[12] 
HAI is very rare below 2 500 m, but any new symptoms occurring 
after ascent above 3 500 m should be presumed to be altitude 
related until proven otherwise. Mild AMS can be managed 
by temporarily halting ascent, simple analgesia and hydration. 
Moderate to severe AMS (or any evidence of HACE or HAPE) 
should result in immediate descent until symptoms subside. 
Adherence to these simple guidelines should minimise the risk of 
an altitude-induced death.
Mountaineers on expeditions on remote peaks traditionally 
make provision for the risk of altitude illness by allowing time for 
acclimatisation, and carrying suitable supplies for treatment if such 
illness should occur. While medication and descent are the mainstay 
of altitude illness, supportive therapy with supplemental oxygen and 
portable hyperbaric chambers can be lifesaving, especially in cases 
where descent is delayed or impossible owing to weather or logistical 
difficulties. Despite the relative accessibility of Kilimanjaro, and while 
many tour operators claim to offer their services, the varying level 
of medical skills and number of groups spread across the mountain 
make availability questionable. Reliance on helicopter rescue in this 
region, even without the limits of altitude, weather, and darkness, is 
inadvisable.
Historically, mountaineering expeditions have been medically 
supported by recreational mountaineers who are doctors and 
who may have very varied backgrounds and medical skills. In 
recent times, however, the importance of providing high-quality, 
evidence-based practice in wilderness, remote and austere settings 
has driven the development and rapid growth of the disciplines 
and formal education in wilderness, expedition and extreme 
medicine.[13] Examples include the Fellowship of the Academy 
of Wilderness Medicine (FAWM)[14] under the auspices of the 
Wilderness Medical Society (WMS), and the Diploma in Mountain 
Medicine (DiMM),[15] under the auspices of the International 
Climbing and Mountaineering Federation (UIAA). As practice 
has evolved, published standards for the education, skills and 
proficiencies of expedition medics have emerged.[16,17] Until very 
recently, these educational opportunities have not been available 
in SA. Currently, however, internationally accredited training 
courses are being offered, and a Wilderness and Expedition 
Medicine Society of Southern Africa (WEMSSA) has been formed.
Owing to the accessibility and popularity of climbing Kilimanjaro 
and other African peaks, practitioners should recognise the significant 
risks of very high altitude ascents and refer participants to accepted 
guidelines and expedition or altitude experts. Doctors wishing to 
serve as expedition medics should undertake formal training and 
obtain experience in the field, whether their role is voluntary or for 
remuneration. Large or specialist groups (such as charity events) are 
encouraged to request the services of an experienced and qualified 
expedition doctor, who can oversee planning, screening, equipment 
and the health of participants on the expedition. Finally, the medical 
fraternity should continue to advocate that individuals do not shy 
from the health benefits to be 
gained from the wilderness, while 
promoting adequate acclimatisation 
for high-altitude adventures and 
actively campaigning against 
itineraries placing participants at 
heightened risk.
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